Compound tracker
LSD.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
9 trial rows 2 update rows Latest checked: May 17, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Phase 1 / Phase 3
Phases tracked
Active not recruiting / Completed / Recruiting
Statuses seen
Trial rows
NCT06809595 Phase 3 Active not recruiting updated May 1, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Jan 29, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; estimated enrollment n=250; actual start 2025-01-29; arms placebo, 50µg MM120, 100µg MM120; primary outcome HAM-A total score change baseline to Week 12. Definium May 7/Apr. 22 releases say screening closed / sample-size re-estimation target 200 and topline expected late 3Q 2026; keep registry and company facts separated.
NCT06741228 Phase 3 Active not recruiting updated May 1, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Dec 11, 2024
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=214; actual start 2024-12-11; primary outcome HAM-A total score change baseline to Week 12; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected early 3Q 2026.
NCT06941844 Phase 3 Active not recruiting updated Mar 13, 2026
- Condition
- Major Depressive Disorder
- Sponsor / institution
- Definium Therapeutics US, Inc.
- Start date
- Apr 14, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/company tracker only; investigational DT120/MM120/lysergide tartrate is not approved and rows do not establish efficacy, safety, label, reimbursement, or access. ClinicalTrials.gov v2: ACTIVE_NOT_RECRUITING; actual enrollment n=149; actual start 2025-04-14; primary outcome MADRS total score change baseline to Week 6; 100µg MM120 vs placebo. Definium May 7, 2026 Q1 release says enrollment complete and topline expected late 2Q 2026.
NCT07061886 Phase 1 Recruiting updated Jul 11, 2025
- Condition
- LSD
- Sponsor / institution
- University of Chicago
- Start date
- Jun 26, 2025
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: LSD
NCT04227756 Phase 1 Completed updated Jan 24, 2024
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- May 19, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT04516902 Phase 1 Completed updated Aug 23, 2022
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jan 1, 2021
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT04558294 Phase 1 Completed updated Oct 21, 2021
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Oct 16, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT01878942 Phase 1 Completed updated Jan 21, 2016
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT02308969 Phase 1 Completed updated Sep 25, 2015
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
Related updates
May 17, 2026 Trial Update Company
Last checked: 2026-05-17 07:00 UTC. Targeted ClinicalTrials.gov searches for Ascend DT120, Definium Ascend, lysergide tartrate MDD Ascend, and DT120 MDD still did not find an Ascend NCT; DT120 MDD search returned older/non-Ascend NCT05407064. Claim boundary: Definium Ascend remains company-release tracked until registry/results artifacts appear; no approval/access/efficacy/safety upgrade.
Source/tracker note
Targeted ClinicalTrials.gov output: Ascend DT120 / Definium Ascend / lysergide tartrate major depressive disorder Ascend = no results; DT120 major depressive disorder returned NCT05407064, not Ascend.
May 15, 2026 Publication Research
PubMed PMID 42131859 reports an analysis of 2015-2019 NSDUH data among U.S. adults who first used LSD at least five years earlier; estimated 4.2% used LSD in the past year, with past-year use declining as time since initiation increased and correlates including perceived lower risk/higher availability and other substance-use variables.
Source/tracker note
Last checked 2026-05-15 UTC. Claim boundary: nonmedical-use epidemiology and public-health context only; self-report survey correlates are not clinical efficacy evidence, therapeutic safety evidence, approval/access evidence, or a basis for causal claims about LSD.
Conditions touched
Generalized Anxiety DisorderHealthyLSDMajor Depressive Disorder